Press Releases

12.03.2012

The Berlin-based biotechnology company MOLOGEN AG has received approval from the responsible German health authority, the Paul-Ehrlich-Institut, to carry out a phase I/II clinical study with its innovative new MGN1601 cancer medicine. MGN1601 is a...

16.03.2012

The MOLOGEN AG Board of Directors completed a capital increase on June 11, 2010 against cash contributions and excluding subscription rights. On the basis of an authorization granted at the Annual General Meeting, as well as the approval of the...

16.03.2012

The Berlin biotech company MOLOGEN has received approval from the competent German and Austrian health authorities at the Paul Ehrlich Institute and the Federal Office for Safety in Health Care (“Bundesamt für Sicherheit im Gesundheitswesen”),...

16.03.2012

The MOLOGEN AG Board of Directors completed a capital increase on January 7, 2010 against cash contributions and excluding subscription rights. On the basis of an authorization granted at the Annual General Meeting, as well as the approval of the...

09.12.2009

  • Licensing-relevant study to examine the efficacy of MGN1703 in the treatment of metastasized colorectal cancer

  • The multicenter study will start immediately after approval

MOLOGEN AG has applied to the...

10.11.2009

  • Application submitted for approval of a clinical study I/II

  • Second MOLOGEN product candidate moves into clinical phase
The Berlin-based biotechnology company MOLOGEN AG submitted an application for approval of...

09.11.2009

  • Promising cancer drug set to enter second stage of development
  • New patents in the US for innovative product candidates
MOLOGEN AG made significant clinical advances in the third quarter of the current fiscal year: The...

   

Displaying results 1 bis 7 von 37

Page 1

Page 2

Page 3

Page 4

Page 5

Page 6

next

   

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com